Stockholm/Cambridge, Massachusetts — Medivir AB (Nasdaq Stockholm: MVIR) and
Trek Therapeutics (TREKtx) today announced that TREKtx has licensed the
exclusive rights to develop and commercialize MIV-802 globally, excluding China,
Taiwan, Hong Kong and Macau. MIV-802 is a nucleotide polymerase inhibitor under
development for the treatment of hepatitis C virus (HCV) infection.
Under the terms of the agreement, Medivir is entitled to receive milestones
based on successful clinical development and royalties capped at a mid-teens
percentage upon commercialization of MIV-802 containing products. BioPhausia, a
subsidiary of Medivir, is granted options to commercialize MIV-802 containing
products in the Nordics and certain Western European countries. Other terms of
the transaction were not disclosed.
“We are pleased to have Trek Therapeutics as a partner with their deep knowledge
of HCV drug development, and their mission to make competitive treatments
accessible to world populations” said Niklas Prager, CEO of Medivir.
TREKtx is developing combination treatments for HCV utilizing its portfolio of
antiviral agents including faldaprevir, a protease inhibitor, TD-6450, a NS5A
inhibitor, and lomibuvir, a non-nucleoside NS5B inhibitor.
“Nucleotides are essential components of combination regimens to provide a short
duration of treatment with low levels of resistance.” said Ann Kwong, Ph.D., CEO
of TREKtx. “We are excited to develop MIV-802 as part of a highly-effective
combination treatment to address HCV.”
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Jane A. Kramer, Trek Therapeutics, e-mail: firstname.lastname@example.org. Phone: +1-781
Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 08.45 CET on 17 August 2016.
MIV-802 is a potent, pangenotypic nucleotide inhibitor of the HCV NS5B
polymerase. Hepatitis C treatments comprise combinations of pharmaceuticals with
different antiviral mechanisms. Preclinical data indicate that MIV-802 can be
used effectively in combination with other classes of antiviral agents for the
treatment of HCV, including protease inhibitors, non-nucleoside NS5B inhibitors,
and NS5A inhibitors.
Medivir is a research based pharmaceutical company with a research focus on
oncology and infectious diseases. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need.
BioPhausia is a wholly-owned subsidiary of Medivir, with a portfolio of
prescription pharmaceuticals made available for the Nordic market. Medivir is
listed on the Nasdaq Stockholm Mid Cap List.
About Trek Therapeutics
Trek Therapeutics, PBC is a private, clinical stage public benefit corporation
developing treatments for serious infections. Its mission is to profitably
develop affordable and accessible medicines to treat infectious diseases and to
commercialize them for global populations. TREKtx is currently conducting phase
II clinical trials in patients with chronic HCV infection using a combination of
direct acting antivirals, and is also evaluating treatments for other infectious
diseases. For further information, please visit www.trektx.com.